2024-12-31 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis Report

**1. Performance Comparison and Divergence:**

Johnson & Johnson (JNJ), a global healthcare company that manufactures and sells a wide range of medical devices, pharmaceuticals, and consumer products, has significantly underperformed the S&P 500 (VOO) over the measured period.  The cumulative return for JNJ is 21.55%, while the S&P 500's cumulative return is 115.96%. This represents a substantial difference of -94.4%, placing it at the 4.8th percentile of its historical relative performance against the S&P 500 based on the provided data. The provided CAGR data shows fluctuating performance with some periods of outperformance and periods of significant underperformance against the benchmark. The alpha consistently measures around 0 suggesting no outperformance on a risk-adjusted basis.

**2. Recent Price Movement:**

* **Closing Price:** $143.34
* **5-Day Moving Average:** $145.02
* **20-Day Moving Average:** $147.15
* **60-Day Moving Average:** $154.82

The current price is below all three moving averages, indicating a downward trend in the short to medium term.

**3. Technical Indicators and Expected Return:**

* **RSI (31.23):** Suggests the stock is currently in oversold territory.
* **PPO (0.063):** Indicates a weak bullish momentum.
* **Relative Strength Divergence:**  A recent 20-day decline in relative strength is observed.
* **Expected Return (-543.6%):** This extremely negative figure suggests a significant projected underperformance against the S&P 500 over the long term (2+ years) based on the current situation. This warrants careful consideration and further investigation.  It is crucial to understand how this figure was derived to interpret its reliability.


**4. Recent Earnings Analysis:**

The reported EPS and revenue show some volatility.  While revenue has remained relatively stable around $22B, EPS has fluctuated considerably across quarters.  The most striking observation is the exceptionally high EPS of $10.32 reported in the quarter ending 2023-10-27, significantly exceeding the other quarters' reported EPS.  Without access to analyst expectations, it's impossible to determine whether any quarters represented "beats" or "misses."

**Revenue Growth Trends:** Revenue shows relatively flat growth, with minor fluctuations between quarters, showing no clear consistent upward or downward trend within the provided data.

**EPS Trends and Significant Changes:** The EPS is highly volatile, lacking consistency.  The outlier of $10.32 in Q4 2023 requires investigation to understand the underlying factors.

**5. Financial Information Analysis:**

* **Revenue and Profitability:** Revenue is relatively stable, with slight fluctuations. Profit margins are consistently high (68-70%), indicating strong profitability.
* **Capital and Profitability:** Equity fluctuates. ROE is highly volatile, with an exceptionally high value (36.54%) in Q3 2023 that needs further investigation to determine the contributing factors.  This volatility warrants deeper analysis to understand the underlying drivers of these changes.


**6. News and Recent Issues:**

* **Earnings News (Last 2 Days):**  Information on earnings news from the last two days is not provided.
* **Recent Market Outlook:** Not specified.
* **Analyst Opinions:**  No analyst opinions are provided.

**7. Overall Analysis:**

JNJ's recent performance has significantly lagged the S&P 500.  While profitability remains strong, recent earnings have shown significant EPS volatility, requiring further investigation into the causes of this fluctuation, particularly the exceptionally high EPS in Q4 2023.  The extremely negative long-term expected return highlights significant risk.  Technical indicators suggest oversold conditions, but the price is trending downwards. The lack of information regarding recent news and analyst opinions limits a comprehensive assessment. More data and context are needed for a full and reliable evaluation of JNJ's current investment prospects.

**8.  Recommendations:**

Given the information provided, a strong cautionary approach is advised.  The substantial underperformance against the benchmark, coupled with the volatility in earnings and the highly negative projected return, raises significant concerns.  Further investigation into the causes of the unusual Q4 2023 EPS figure, and obtaining current market outlook and analyst opinions are crucial before making any investment decisions.  Due diligence and additional research are absolutely necessary before considering any action.
